Chiesa, Morgane
Ferrari, Diana C.
Ben-Ari, Yehezkel
Funding for this research was provided by:
Neurochlore
Fondation Bettencourt Schueller
Agence Nationale de la Recherche (ANR-14-CE13-0021-01)
CIFRE-ANRT (2014/1056)
Article History
Received: 13 August 2019
Accepted: 2 March 2020
First Online: 9 March 2020
Ethics approval and consent to participate
: Experiments were performed in accordance with the European Communities Council Directive (2010/63/EU) and approved by the Local Ethics Committee (C2EA #14) and the French Ministry of Higher Education, Research and Innovation (agreement number #17300–2018102610588631).
: Not applicable.
: YBA and DCF are shareholders of Neurochlore, a biotech company dedicated to the development of treatments for children with autism. YBA is also the CEO of the company. MC and DCF are employed by Neurochlore.